Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
72.11
+0.73 (1.02%)
Feb 21, 2025, 4:00 PM EST - Market closed
Incyte Employees
Incyte had 2,524 employees as of December 31, 2023. The number of employees increased by 200 or 8.61% compared to the previous year.
Employees
2,524
Change (1Y)
200
Growth (1Y)
8.61%
Revenue / Employee
$1,680,355
Profits / Employee
$12,922
Market Cap
13.96B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,524 | 200 | 8.61% |
Dec 31, 2022 | 2,324 | 230 | 10.98% |
Dec 31, 2021 | 2,094 | 321 | 18.10% |
Dec 31, 2020 | 1,773 | 317 | 21.77% |
Dec 31, 2019 | 1,456 | 89 | 6.51% |
Dec 31, 2018 | 1,367 | 159 | 13.16% |
Dec 31, 2017 | 1,208 | 228 | 23.27% |
Dec 31, 2016 | 980 | 288 | 41.62% |
Dec 31, 2015 | 692 | 104 | 17.69% |
Dec 31, 2014 | 588 | 107 | 22.25% |
Dec 31, 2013 | 481 | 68 | 16.46% |
Dec 31, 2012 | 413 | 45 | 12.23% |
Dec 31, 2011 | 368 | 121 | 48.99% |
Dec 31, 2010 | 247 | 26 | 11.76% |
Dec 31, 2009 | 221 | 9 | 4.25% |
Dec 31, 2008 | 212 | 16 | 8.16% |
Dec 31, 2007 | 196 | 10 | 5.38% |
Dec 31, 2006 | 186 | 9 | 5.08% |
Dec 31, 2005 | 177 | -9 | -4.84% |
Dec 31, 2004 | 186 | -268 | -59.03% |
Dec 31, 2003 | 454 | -37 | -7.54% |
Dec 31, 2002 | 491 | -94 | -16.07% |
Dec 31, 2001 | 585 | -737 | -55.75% |
Dec 31, 2000 | 1,322 | 214 | 19.31% |
Dec 31, 1999 | 1,108 | 241 | 27.80% |
Dec 31, 1998 | 867 | 191 | 28.25% |
Dec 31, 1997 | 676 | 218 | 47.60% |
Dec 31, 1996 | 458 | -2,159 | -82.50% |
Jan 1, 0002 | 2,617 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
INCY News
- 2 days ago - Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration - Business Wire
- 4 days ago - Incyte to Present at Upcoming Investor Conferences - Business Wire
- 10 days ago - Reevaluating Incyte Corporation After Earnings (Technical Analysis) - Seeking Alpha
- 11 days ago - Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025 - Seeking Alpha
- 11 days ago - Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Incyte reports quarterly sales above estimates on strong demand for key drugs - Reuters
- 12 days ago - Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones - Business Wire
- 14 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire